Arax Advisory Partners’s Takeda Pharmaceutical TAK Stock Holding History

Arax Advisory Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$629K	Buy	39,210 +34,867	+803%	+$577K	﹤0.01%	1490
2026 Q1	$80.4K	Sell	4,343 -2,835	-39%	-$49.8K	﹤0.01%	1489
2025 Q4	$112K	Sell	7,178 -53,996	-88%	-$772K	﹤0.01%	1283
2025 Q3	$896K	Buy	61,174 +60,401	+7,814%	+$897K	0.01%	681
2025 Q2	$88.4K	Buy	773 +539	+230%	+$7.96K	﹤0.01%	985
2025 Q1	$3.48K	Buy	+234	New	+$3.28K	﹤0.01%	1915
2024 Q4	–	Sell	-1,556	Closed	-$22.1K	–	2737
2024 Q3	$22.1K	Sell	1,556 -358	-19%	-$5.08K	﹤0.01%	1043
2024 Q2	$24.8K	Sell	1,914 -42	-2%	-$556	﹤0.01%	901
2024 Q1	$27.2K	Buy	1,956 +420	+27%	+$6.11K	﹤0.01%	616
2023 Q4	$21.9K	Buy	1,536 +4	+0.3%	+$57	﹤0.01%	634
2023 Q3	$23.7K	Sell	1,532 -32	-2%	-$495	﹤0.01%	557
2023 Q2	$24.6K	Buy	1,564 +412	+36%	+$6.75K	﹤0.01%	554
2023 Q1	$19K	Buy	+1,152	New	+$18.4K	﹤0.01%	593
2022 Q2	–	Sell	-201	Closed	-$3K	–	1238
2022 Q1	$3K	Buy	201 +100	+99%	+$1.47K	﹤0.01%	899
2021 Q4	$1K	Buy	+101	New	+$1.42K	﹤0.01%	1086
2021 Q3	–	Sell	-2,372	Closed	-$40K	–	1071
2021 Q2	$40K	Buy	+2,372	New	+$40.4K	0.01%	499
2020 Q4	$40K	Hold	2,200	–	–	0.01%	438
2020 Q3	$39K	Hold	2,200	–	–	0.01%	417
2020 Q2	$39K	Hold	2,200	–	–	0.01%	402
2020 Q1	$33K	Hold	2,200	–	–	0.01%	403
2019 Q4	$43K	Hold	2,200	–	–	0.01%	356
2019 Q3	$38K	Buy	2,200 +1,000	+83%	+$17.3K	0.01%	362
2019 Q2	$21K	Buy	+1,200	New	+$21.8K	0.01%	405
2018 Q4	$20K	Buy	+1,200	New	+$20.3K	0.01%	368

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Arax Advisory Partners's TAK Position: Q2 2026 in Review

Arax Advisory Partners increased its Takeda Pharmaceutical (TAK) stake by 803% in Q2 2026, buying an estimated $577K and bringing the position to 39,210 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

Arax Advisory Partners first reported a position in TAK in Q4 2018 and has held it in 24 quarters since. The position peaked at $896K in Q3 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Arax Advisory Partners held 39,210 shares of Takeda Pharmaceutical worth $629K as of Q2 2026.
Arax Advisory Partners bought 34,867 Takeda Pharmaceutical shares in Q2 2026, an estimated $577K.
Takeda Pharmaceutical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1490 holding.
Arax Advisory Partners first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 24 quarters since.
Arax Advisory Partners's Takeda Pharmaceutical position peaked at $896K in Q3 2025.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.